Biotest Italia s.r.l.

What Biotest Italia s.r.l. does

Biotest Italia s.r.l. was an Italian private limited company (s.r.l.) founded in 1968 and headquartered in Trezzano Sul Naviglio, Milano. It operated as the Italian distribution subsidiary of Biotest AG, a German pharmaceutical company specializing in immunology and hematology. Functionally, the entity was a specialty pharmaceutical distributor: it channeled Biotest AG's plasma-derived therapeutic products — principally immunoglobulins and coagulation factors — to Italian healthcare providers, pharmacies, and medical facilities. With 16 employees and no disclosed product portfolio of its own, its value lay in regulated access to the Italian market, pharmacovigilance infrastructure, and customer relationships with domestic hospital and pharmacy networks rather than in proprietary R&D or manufacturing capability.

The company's revenue mechanics were that of a captive distributor: it bought Biotest AG products and resold them within Italy under the parent's brand and licenses. Pricing details, customer mix, contract structures, and revenue figures are not disclosed in the source material. Go-to-market was direct B2B distribution into the Italian healthcare system, with marketing channels (LinkedIn, XING, Instagram, Facebook, X/Twitter) handled at the Biotest AG corporate level rather than locally. The operating geographies listed (Italy, Germany, Austria, Switzerland, Hungary) reflect Biotest AG's broader European footprint rather than independent expansion by Biotest Italia itself.

On February 1, 2024, Grifols Italia Spa acquired and fully integrated Biotest Italia s.r.l. Following the acquisition, the entity ceased independent operations. All product orders were redirected to Grifols Italia ([email protected] / 050/8755111 ext 3), medical information requests to [email protected], and adverse event reporting to [email protected] via the Grifols Italia portal. The current operating status is recorded as "acquired"; the company no longer functions as a standalone commercial entity.

Name

Biotest Italia s.r.l.

Legal name

Biotest Italia s.r.l.

Website

https://biotest.it

Company type

Private

Operating status

Acquired

Headcount range

11–50 employees

Short description

Biotest Italia s.r.l. was the Italian distribution arm of Biotest AG, channeling plasma-derived therapeutics (immunoglobulins, coagulation factors) to Italian hospitals, pharmacies, and medical facilities. As of February 2024, it was acquired and integrated into Grifols Italia Spa.

Ownership category

akta.pro rank

GTM type

B2B

Offering type

Services

Cost components

Supply Chain, Operations, Personnel, Marketing or Sales

Distribution channels1 record

Marketing channels5 records

Core offering

Biotest Italia s.r.l. was the Italian distribution subsidiary of Biotest AG, supplying plasma-derived pharmaceutical products including immunoglobulins, coagulation factors, and other hematology and immunology therapeutics to Italian healthcare providers. As of February 1, 2024, the company was acquired and integrated into Grifols Italia Spa, and orders are now handled through Grifols Italia.

Product overview

Biotest Italia s.r.l. was an Italian subsidiary of Biotest AG, a pharmaceutical company specializing in immunology and hematology products. As of February 1, 2024, Biotest Italia s.r.l. has been acquired and integrated into Grifols Italia Spa. The website indicates that Biotest products continue to be available through Grifols Italia for ordering purposes.

Differentiator

Problem solved

Functional benefit

Products and services

• Plasma-derived therapeutics distribution

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Grifols Italia SpacoreStrategic or Co-development Partner · 1 February 2024Grifols Italia Spa acquired and integrated Biotest Italia s.r.l. effective February 1, 2024. All Biotest product orders in Italy are now directed to Grifols Italia. Medical information requests should be sent to [email protected]. Adverse event reporting is handled through Grifols Italia at [email protected], with additional resources available at www.grifols.com/en/italy.

Recent moves3 records

Expansion highlights2 records

Direct peers

• Kedrion Biopharma: Italian-headquartered plasma-derived therapy company with a similar product mix of immunoglobulins, coagulation factors, and albumin. Directly comparable as a domestic Italian player in the same therapeutic categories Biotest Italia distributed.
• Grifols Italia Spa: Italian subsidiary of Grifols and the acquirer of Biotest Italia. Operates as the primary distributor of plasma-derived therapeutics in Italy, directly overlapping with Biotest Italia's product portfolio and customer base in immunology and hematology.
• CSL Behring Italia: Italian arm of CSL Behring, a global leader in plasma-derived therapies. Distributes the same therapeutic categories (immunoglobulins, coagulation factors) to Italian hospitals and specialty pharmacies through a similar commercial model.
• Octapharma Italia: Italian subsidiary of Octapharma, focused on plasma-derived therapies including coagulation factors and immunoglobulins. Closely comparable in product portfolio and Italian distribution footprint.

Broad incumbents

• Biotest AG: German parent company and manufacturer of the plasma-derived products Biotest Italia distributed. Provides the upstream product supply and is the source of the brand equity Biotest Italia leveraged in Italy.
• Takeda Italia: Italian subsidiary of Takeda with a strong hematology and rare disease portfolio that overlaps Biotest Italia's therapeutic areas. Larger and broader in scope than Biotest Italia but competes for the same specialist prescriber base.
• Roche Italia: Italian subsidiary of Roche with significant hematology and immunology offerings. Operates in the same Italian hospital and specialty distribution environment as Biotest Italia.
• Sanofi Italia: Italian operations of Sanofi, which has a significant immunology and rare disease franchise. Competes in overlapping therapeutic areas with a much broader specialty and primary-care portfolio.
• Pfizer Italia: Italian arm of Pfizer with a broad pharmaceutical portfolio that includes hematology products. Comparable as a large multinational pharmaceutical distributor operating in the same Italian healthcare channels.

Emerging players

• Sobi Italia: Italian operations of Swedish Orphan Biovitrum, focused on rare hematology and immunology products. Comparable as a specialty distributor of plasma-derived and biologic therapies into the same Italian hospital channels.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights4 records

Customer concentration

• Xx.com/BiotestAG
• Facebookfacebook.com/BiotestAG
• LinkedInlinkedin.com/company/biotest-italia
• Instagraminstagram.com/biotest_ag

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biotest Italia s.r.l.